3D Models of Surrogate Multiple Myeloma Bone Marrow Microenvironments: Insights on Disease Pathophysiology and Patient-Specific Response to Drugs by Ferrarini, Marina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







3D Models of Surrogate 
Multiple Myeloma Bone Marrow 
Microenvironments: Insights on 
Disease Pathophysiology and 
Patient-Specific Response to Drugs
Marina Ferrarini, Magda Marcatti, Fabio Ciceri  
and Elisabetta Ferrero
Abstract
Multiple Myeloma (MM) develops almost exclusively within the Bone Marrow 
(BM), highlighting the critical role of the microenvironment in conditioning disease 
progression and resistance to drugs. Indeed, while the therapeutic armamentarium for 
MM has significantly improved over the past 20 years, the disease remains ultimately 
incurable. This failure may depend on the high phenotypic and genetic heterogeneity 
of MM, but also on the paucity and inadequacy of two-dimensional (2D) conventional 
preclinical models in reproducing MM within the BM. In the present paper, we pro-
vide a brief updated overview on MM BM microenvironment. We then discuss newly 
developed preclinical models mimicking MM/microenvironment interactions, includ-
ing three-dimensional (3D), gel-based, in vitro models and a novel ex vivo system of 
isolated tumor and stromal cells cultured in bioreactor. Potential applications of each 
model, relative to investigation of MM pathogenic mechanisms and prediction of the 
best drug/combination for each individual patient will be also evaluated.
Keywords: multiple myeloma, tumor microenvironment, 2D/3D culture models,  
3D culture in bioreactor, drug testing, personalized therapy
1. Introduction
Multiple Myeloma (MM) is a B-cell tumor characterized by clonal proliferation 
of malignant plasma cells (PC) inside the bone marrow (BM), production of a 
monoclonal paraprotein and associated clinical features, including hypercalcemia, 
renal failure, anemia and lytic bone lesions (CRAB features) [1, 2].
MM is the second most common hematological malignancy and is responsible for 
approximately 20% of deaths from hematological tumors. Despite significant advances 
in therapy over the past two decades, the disease remains incurable, and more than 90% 
of MM patients eventually become refractory to therapy and relapse [1, 2].
MM develops along an evolutionary process, leading a normal PC to the pre-
malignant state of monoclonal gammopathy of uncertain significance (MGUS), 
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an intermediate asymptomatic but more advanced pre-malignant state referred 
to as smoldering MM (SMM) and finally to symptomatic MM [3–6]. This process 
is driven by the accumulation of cytogenetic modifications in PC. Indeed, while 
MM is still considered a single disease entity, it should be viewed as a collection of 
several different cytogenetically distinct PC tumors [7]. Cytogenetic abnormalities 
encompass translocations involving the immunoglobulin heavy chain (IgH) gene 
locus on chromosome 14q32 and hyperdiploidy (particularly trisomies), as initiat-
ing events [8]. IgH translocations include t(4;14), t(6;14), t(11;14), t(14;16) and 
t(14;20) translocations, which place the oncogenes Multiple Myeloma SET domain 
(MMSET)/ fibroblast growth factor receptor 3 (FGFR3), cyclin D3 (CCND3), 
CCND1, MAF, and MAFB, respectively, under the control of the strong enhanc-
ers of the Ig loci. This in turn leads to over-expression of cyclin D protein family 
members, ultimately driving G1/S checkpoint dysregulation [9, 10]. Hyperdiploidy, 
which is associated with the gain of the odd numbered chromosomes, including 
chromosome 3, 5, 7, 9, 11, 15, 19 and 21, also affects this checkpoint, implicat-
ing cyclin D dysregulation as an early and unifying oncogenic event in MM [9]. 
Subsequent studies demonstrated that other cytogenetic changes termed secondary 
cytogenetic abnormalities, including gain(1q), del(1p), del(17p), del(13), RAS 
mutations and secondary translocations involving MYC, arise along the disease 
course of MM, exacerbating the cell cycle dysregulation and driving further 
proliferation and disease progression [10, 11]. Patients carrying del(17p), t(4;14), 
t(14;16), t(14;20), gain(1q), or p53 mutation, particularly when in combination 
(double-hit and triple-hit myeloma), are considered affected by high-risk MM [11], 
and represent an area of unmet clinical need [8].
In addition to genetic abnormalities, a characteristic feature of myeloma cells 
is the requirement for an intimate relationship with the BM microenvironment, 
where plasma cells are nurtured in specialized niches that maintain their long-
term survival. Indeed, BM components deeply influence many steps of tumor 
progression, such as MM proliferation and invasion, angiogenesis and drug 
resistance [12, 13].
The BM, where MM cells specifically home mainly through the CXCR4/CXCL12-
SDF1α axis [14], provides a highly specialized microenvironment, which optimally 
“soils” neoplastic PC, and, in turn, is shaped by the interactions with the tumor [15, 
16]. The BM microenvironment comprises two major compartments, i.e., the cel-
lular and the non-cellular compartment. The latter includes the extracellular matrix 
(ECM), consisting of collagen I to XI, fibronectin, glycoproteins, matrix proteogly-
cans and glycosaminoglycans, as well as the liquid milieu (cytokines, chemokines 
and growth factors). The cellular compartment consists of a series of components, 
including BM stromal cells (BMSC), hematopoietic cells, osteoclasts, osteoblasts, 
endothelial cells (EC), adipocytes and immune cells. Inside the BM milieu MM 
cells realize a complex interplay involving both cellular and ECM components 
through the engagement of adhesion molecules and the release of soluble factors, 
including cytokines, growth factors and exosomes [12]. Exosomes are extracellular 
membranous vesicles known to facilitate the transfer of biologically active mol-
ecules, including proteins and nucleic acids (particularly microRNAs -miRNAs), 
from the original producing cell to the target cell [17]. Exosomes are released by 
almost all cell types and, depending on their cargo, can induce target cell activation, 
proliferation/differentiation or death, thus playing a key role in the regulation of 
physiological as well as pathologic processes, including malignant transformation 
[17]. In MM, exosomes have been recently shown to reprogram the BM microenvi-
ronment, creating a niche for tumor PC and favoring their expansion and the onset 
of pharmacological resistance [18–20].
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Another key feature of the BM microenvironment is hypoxia. In the BM, oxygen 
(O2) tensions fluctuate throughout two specialized niches, the hypoxic endosteal 
niche and the oxygenated vascular niche, mapping areas with controlled, physi-
ological O2 gradients, instrumental to hematopoietic stem cells homeostasis [21]. 
BM homing is a common feature of hematological malignancies, that in proximity 
of hypoxic niches escape drug-inflicted apoptosis and acquire a drug-resistant 
phenotype. This is particularly true for MM that develops almost exclusively in the 
BM, where myeloma cells accumulation and the abnormal vasculature contribute 
to aggravate hypoxia. BM samples from MM patients as well as circulating MM 
cells are reported to have a hypoxic phenotype [22] and a strong stabilized expres-
sion of the hypoxia master regulator hypoxia-inducible factor (HIF)-1α protein 
[23]. Notably, HIF-1α suppression in myeloma cells blocks tumor growth in vivo 
and interferes negatively with angiogenesis and bone destruction [24]. In addition 
to conventional cell contact-dependent and -independent signaling pathways, 
hypoxia promotes MM survival and drug resistance through alternative mecha-
nisms. Hypoxia is indeed a major regulator of exosomal content and angiogenesis 
in MM settings [25]. Moreover, hypoxia shifts the metabolic profile of MM cells 
toward elevated glycolysis and production of lactate, as a strategy to support 
energy requirement [26]. Notably, knockdown of lactate restores MM sensitivity to 
bortezomib, overall suggesting that targeting hypoxia and MM energy metabolism 
could alleviate drug resistance [26].
Overall, the cross-talk between MM cells and their BM microenvironment results 
in autocrine/paracrine loops of MM survival/proliferation and also promotes the 
“angiogenic switch”, osteoclastogenesis, and defective immune functions [12, 13]. In 
particular, adhesion of MM cells to ECM components and to BMSC triggers classical 
survival signaling pathways including, but not limited to, the PI3K/AKT signal-
ing pathway, anti-apoptotic signals and also the release of the pro-survival factor 
Interleukin (IL)-6 [27]. MM cells-BM interactions also play a key role in disease 
pathogenesis. In particular, new blood vessel formation is considered a hallmark of 
MM development and is supported by the histopathological evidence of increased 
microvessel density (MVD), surrogate parameter endowed with prognostic signifi-
cance, in the BM of MM patients [28]. Angiogenesis, the sprouting of capillaries 
from existing blood vessels, is also suggested by the plethora of soluble angiogenic 
factors in the BM and in the peripheral blood (PB) samples from myeloma patients 
(vascular endothelial growth factor, VEGF; basic fibroblast growth factor, bFGF; 
angiopoietins, Angs) [29, 30], whose contribution to the process has been exten-
sively reviewed [31]. Moreover, the finding of an elevated number of circulating 
endothelial precursor cells (EPC) in MM patients indicates that complementary 
modalities to build vessels, e.g., vasculogenesis, are engaged [31]. Finally, EC are by 
nature fine sensors of O2 variations, and the hypoxic microenvironment inside the 
BM significantly contributes to the induction of the “angiogenic switch” and the 
maintenance of the pro-angiogenic profile through the transcription of HIF-1α [32].
MM plasma cells and BM stroma also contribute to the pathophysiology of 
MM-associated bone disease through the activation of signaling pathways regulat-
ing osteoclastogenesis, particularly the RANK/RANK-Ligand (RANK-L) and the 
Wnt pathway, and the release of osteoclast-activating factors, such as IL-1, IL-6, 
tumor necrosis factor (TNF)-α, IL-8 and Macrophage Inflammatory Protein 
(MIP)-1α. These factors, together with recently identified dysregulated miRNAs, 
determine osteoblast suppression with excessive osteoclastic resorption [33]. 
Finally, MM cells display a unique ability to evade immune surveillance through 
several mechanisms, including impairment of cytotoxic activity, induction of 
dendritic cell dysfunction and recruitment of regulatory cells [34].
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2. 3D models of MM microenvironment for precision medicine
2.1  Therapeutic targeting of MM cells and their BM microenvironment: toward 
personalized therapy
Over the past 20 years, progressive understanding of the pathophysiology of 
MM has informed treatment paradigm and patients’ outcome [35]. In particular, the 
introduction into the clinical practice of novel agents, such as proteasome inhibitors 
(PI) and immunomodulatory drugs (IMiDs), has prolonged median survival of 
MM patients from 3 to about 6 years, reaching approximatively 8 years in the subset 
of patients eligible to autologous stem cell transplantation (ASCT) [11].
The proteasome inhibitor bortezomib targets MM cells harnessing their depen-
dency on the protein quality control pathway as a therapeutic target [36]. The 
ubiquitin-proteasome system represents a major mechanism for maintaining pro-
tein homeostasis, which is strictly required by normal antibody secreting PC, and 
particularly by MM PC [36]. Bortezomib causes an imbalance between proteasome 
degradative capacity and proteasome load, leading to the activation of the unfolded 
protein response, and ultimately to cell death via both intrinsic and extrinsic 
mechanisms of MM cell apoptosis [37]. Moreover, bortezomib affects viability of 
angiogenic EC [38], as well as bone turnover and osteoclast activity in the BM [39].
Given the key role of BM components in supporting MM cell proliferation, 
migration, survival and drug resistance, while also conferring immunosuppression, 
disrupting MM cells-BM interactions represents an alternative therapeutic strategy 
in MM. IMiDs, including thalidomide and its more potent derivatives lenalidomide 
and pomalidomide, have received Food and Drug Administration (FDA) approval 
for treatment of both newly diagnosed and relapsed/refractory MM [35]. IMiDs 
bind to cereblon (CRBN) and activate CRBN E3-ligase activity, causing the rapid 
ubiquitination and degradation of two specific B cell transcription factors, Ikaros 
(IKZF1) and Aiolos (IKZF3) [40, 41]. IMIDs thus exert direct cytotoxic effects on 
MM cells, including growth arrest, free radical-mediated DNA damage and cas-
pase-8-mediated apoptosis; moreover, they modulate cytokine and growth factor 
secretion, inhibit angiogenesis, and, most importantly, upregulate T, NK, and NKT 
cytotoxicity, while downregulating regulatory T cells [42].
Over the disease course, however, MM cells acquire resistance to bortezomib 
and IMiDs through genetic and non-genetic mechanisms [36, 43]. To overcome 
resistance, second-generation PI (carfilzomib, ixazomib) and higher affinity CRBN 
E3-ligase modulators, such as iberdomide, have been developed [35, 36]. Alternative 
therapeutic approaches include: targeting epigenetic modifications via the Histone 
deacetylases (HDAC) inhibitors (panobinostat, ricolinostat); targeting the tumor-
BM microenvironment interface via immune-based therapies, including mono-
clonal Antibodies (mAb) directed against MM surface antigens (elotuzumab and 
daratumumab, targeting SLAMF7 and CD38, respectively) and cellular therapies to 
boost MM- specific immunity, including adoptive T-cell therapy (ACT), engineered 
T-cell approaches and vaccines [35, 44]. Notably, progress in engineering technolo-
gies allowed for chimeric antigen receptor (CAR) T-cell approaches [45]. CAR are 
chimeric proteins that bring together the signaling moieties of the T cell receptor 
(TCR) complex and the variable domains of an Ab recognizing a tumor-associated 
antigen (in MM, most frequently the B cell maturation antigen –BCMA-, due to 
its selectivity for normal PC and MM cells) [35]. As a result, in the last decade, 
carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, daratumumab, 
isatuximab, and selinexor (a selective inhibitor of nuclear export of tumor suppres-
sor proteins and growth factors) have received FDA approval for the treatment of 
relapsed MM, and are expected to improve outcomes further [11].
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To date, therapy for an individual MM patient is selected based on clinical 
factors, such as age, performance status, comorbidities and eligibility for ASCT 
[46]. Given the high heterogeneity of the disease in terms of underlying molecular 
aberrations and clinical course, and also the growing armamentarium of currently 
available effective agents, this approach can be updated by the use of evidence-
based algorithms [46], but it also needs to be implemented by incorporating 
prognostic and predictive biomarkers for survival and response to treatment [8]. 
Indeed, thanks to the progressive evolution and clinical utilization of molecular 
technologies, such as fluorescence in situ hybridization (FISH) and next-generation 
sequencing (NGS), we can foresee that in the near future the choice of therapy may 
include selection of targeted treatments based on the presence of specific molecular 
lesions, thus achieving personalized cancer care for MM patients [8]. Such treat-
ments can be validated through randomized controlled clinical trials [8]; however, 
the development of reliable patient-specific pre-clinical models would also be 
valuable in the perspective of defining personalized, biologically based treatments 
for MM patients, while preventing ineffective therapy of resistant MM cells and 
unwanted toxicities [47].
2.2 In vitro models of cancer: moving from 2D to 3D
It is increasingly recognized that microenvironment plays a fundamental role 
in supporting tumor cell growth, survival and drug resistance; thus, experimental 
models of cancer should incorporate elements of the surrounding milieu to recre-
ate and unveil the mechanisms that, at the molecular level, regulate the complex 
interplay between tumor cells and their embedding niche(s).
Traditional two-dimensional (2D) in vitro cultures, i.e., static cultures of cells 
kept on flat, artificial surfaces, still represent the most popular models for in vitro 
studies. These culture systems have so far provided invaluable information on the 
basic molecular principles of cancer; it is becoming progressively clear, however, 
that they present severe limitations, since they fail to reproduce adequately mor-
phology, behavior, and functions of normal and pathologic cell types and tissues 
[48]. It is now generally agreed that the generation of reliable and physiologically 
relevant in vitro tissue analogues, tumors included, should rely upon reproducing 
(or preserving) the specific characteristics of the native microenvironment. These 
encompass tissue-specific multiple cellularity and architecture, biochemical and 
mechanical cues, cell–cell and cell-ECM interactions and particularly the three-
dimensionality (3D) [48, 49]. Indeed, since the pioneering work of Bissell and 
colleagues [50], several groups have extensively demonstrated that both normal and 
transformed cells maintained in traditional 2D culture significantly differ from cells 
kept in 3D culture in their biological behavior, gene expression profile and drug 
sensitivity [51–53].
Tissue engineering and regenerative medicine, originally aimed at developing 
biological substitutes of tissues or whole organs, have been subsequently extended 
to the generation of 3D platforms attempting to overcome the limitations of con-
ventional culture models [54]. These platforms are based on different approaches, 
also depending on the aims to be addressed [49]. In particular, several experimental 
approaches rely on the use of polymeric substrates with tunable composition and 
stiffness, as scaffolds or hydrogel-based models. Scaffolds are key elements for the 
generation of 3D platforms, since they provide the mechanical support and physical 
composition for seeded cells to attach, grow and maintain their specialized func-
tions. A suitable scaffold, such as a bone scaffold, must have favorable biocompat-
ibility or cyto-compatibility and also adequate pore size and interconnectivity, 
in order to guarantee the growth, differentiation and proper penetration and 
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distribution of different cell types [55]. Hydrogels are meant to mimic the ECM, 
and can be either natural or synthetic, the former commonly made with natural 
polymers (fibrinogen, hyaluronic acid, collagen, Matrigel and gelatin). Synthetic 
hydrogels are instead typically made with synthetic polymers (polyethylene glycol, 
polylactic acid, or poly-vinyl acetate) [49].
Scaffold-free models include spheroids and organoids. Spheroids are clusters 
of cells forced to assemble through hanging drop techniques or culture in bioreac-
tor, taking advantage of the ability of cultured tumor cells to self-aggregate [56]. 
Spheroids derived from tumor cells, commonly referred to as tumorspheres, are 
typically monocultures, and therefore lack the multicellular identity that exists 
in a tumor in vivo. Organoids are cell aggregates, whose formation is driven by 
self-organizing, renewing stem cells, which differentiate in vitro, thus reproducing 
essential aspects of the parental organ [57]. Both structures are being exploited for 
drug testing, given their suitability for high throughput screening technologies. 
In particular, organoids grown from patients’ tumor tissues (tumoroids) give rise 
to 3D structures with a multicellular identity that more faithfully recapitulate the 
complexity of the corresponding tumor they derive from, thus representing an 
advancement toward personalized medicine [58, 59]. The use of bioreactors and 
perfused microfluidic chambers adds to the complexity of the culture method, in 
that it allows a strict control of additional parameters, such as O2, temperature, pH 
or nutrients [54]. Finally, the emerging 3D bioprinting technology has attracted 
increasing attention, based on its potential of manufacturing tissue-engineered 
compounds with well-defined 3D geometry [60]. In particular, these techniques are 
used to build tumor constructs via precise injection of living cells (both tumor and 
stroma) in functional biomaterials (bioinks), thus enabling the spatial–temporal 
control of molecular physical and chemical gradients [60, 61].
2.3 3D models of multiple myeloma
Since hematological malignancies with BM homing are supported by specialized 
niches, the complex BM architecture, together with cellular and molecular compo-
sition and interactions, needs to be replicated in engineered platforms to reproduce 
blood cancer behavior [54]. Indeed, while 2D cultures of established MM cell lines 
have been extensively used in high-throughput drug screening, they fail to repro-
duce BM microenvironment as well as the heterogeneity of MM patients’ cells. The 
use of primary patient-derived MM cells in 2D monocultures or in co-cultures with 
stromal cells maintains the heterogeneity of the sample, but MM cell viability and 
functional interactions are often limited [47]. Finally, several animal models, which 
have been reviewed elsewhere [62–65], have been developed in order to support 
the growth of primary myeloma cells within a 3D microenvironment. While these 
models are more complex and therefore considered as more relevant, they are not 
representative of the human microenvironment. Within this context, 3D in vitro/ex-
vivo human-derived culture systems are emerging as important tools to generate 
new approaches to the understanding of the molecular mechanisms of MM progres-
sion, essential prerequisites for the development of more effective interventional, 
diagnostic and prognostic strategies. The former often involve combination of 
multiple agents with the rationale that combining drugs with different mechanisms 
and targets could maximize their therapeutic efficacy [11]; this also should be taken 
into account in the design of 3D models for MM.
Herein we describe relevant 3D models of MM BM microenvironments that 
were generated exploiting different technical approaches, i.e., gel and solid scaf-
folds –based 3D platforms, 3D models using microfluidics and 3D constructs 
cultured in bioreactor.
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2.3.1 3D platforms using gel scaffolds
In 2008, Kirshner and co-workers reported the first in vitro reconstruction of 
the human MM BM microenvironment through a 3D model termed “rEnd-rBM”. 
This was achieved by means of a proper overlay of matrix components, specifically 
collagen I/fibronectin to reconstruct endosteum-marrow junction (rEnd), and then 
a fibronectin/Matrigel mixture to create the recombinant BM (rBM) compartment, 
on which isolated cells from BM aspirates of MM patients were seeded [66]. Cells 
spontaneously redistributed throughout the gel-matrix 3D substrate, mimicking 
human BM architecture and BM-MM interactions, thus providing a powerful tool 
for understanding MM biology [66]. Strikingly, the reconstructed BM allowed 
the expansion of primary myeloma cells, including the putative cancer stem cell 
fraction embedded within the reconstructed endosteal niche. Moreover, the impact 
of anti-MM drugs, specifically bortezomib and melphalan, on distinct cellular 
compartments inside a 3D architecture could be assessed [66].
More recently, de la Puente et al. [67] developed a novel patient-derived 3D 
tissue-engineered BM culture model complexing BM supernatant of MM patients 
and autologous cells in a gel scaffold prepared from patient-derived plasma 
fibrinogen. The resulting construct contained all the growth factors, enzymes and 
cytokines naturally found in the MM microenvironment of an individual patient, 
better recapitulating the BM niche. The model reproduced the MM BM hypoxic 
gradients; moreover, it allowed ex vivo proliferation of primary MM cells for several 
weeks, and induced resistance in MM cells to various anti-myeloma drugs, such as 
carfilzomib and bortezomib [67].
An additional attempt to mimic the MM niche was performed by Jakubikova 
and colleagues [68], who developed a new 3D co-culture ex-vivo model of primary 
patient-derived MM cells and BMSC within a commercially available hydrogel 
(PuraMatrix). BMSC retained phenotypic and functional properties, together with 
lineage (osteoblastogenic) differentiation capacity. Notably, patient-derived MM 
cells showed increased proliferation and CXCR4 expression; moreover, BM-driven 
cell adhesion mediated drug resistance (CAM-DR) to both novel (IMiDs, bortezo-
mib, carfilzomib) and conventional agents (doxorubicin, dexamethasone, melpha-
lan) was observed in the 3D system and paralleled clinical resistance [68].
Finally, a further advancement was reported by Braham et al [69], who gener-
ated a novel in vitro 3D BM niche model by embedding mesenchymal stromal cells 
(MSC), EC and primary MM cells from patients inside a Matrigel matrix. The 
model harbored the characteristics of a representative tumor microenvironment, 
and was able to support long-term (up to 28 days) survival/proliferation of MM 
cells. The authors successfully exploited this tool to provide the first pre-clinical 
in vitro testing of immunotherapies on primary MM samples inside their tumor 
microenvironment. In fact, they showed that a novel class of engineered immune 
cells, i.e., TCRα/β lymphocytes engineered to express tumor-specific Vγ9 VΔ2 
TCRs (TEGs) [70], were able to infiltrate the 3D construct and efficiently kill MM 
cells [69].
2.3.2 3D platforms using silk scaffolds
Adopting a different strategy, based on the use of a strong, porous silk scaffold, 
MSC were induced to undergo osteogenic differentiation, recreating a mineralized 
3D bone matrix [71]. The model allowed to reproduce proper MM-bone interac-
tions in a standardized context and to study the MM-associated osteogenic process, 
demonstrating the negative impact of myeloma cells on normal bone homeostasis 
[71]. 3D silk scaffolds have also been employed by the same group to develop the 
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first 3D, tissue-engineered BM adipose tissue (MAT) model, useful for elucidating 
the reciprocal interactions between MAT and tumor cells [72].
2.3.3 3D models using microfluidics
Recent technical advances include the tumor lab-on-a-chip, in vitro microfluidic 
devices that provide efficient platforms to recapitulate specific tumor traits, such as 
angiogenesis, hypoxia and tumor–stroma interactions, thus representing promising 
tools for personalized medicine [73]. In particular, functional hematopoietic niches 
have been constructed by culturing and perfusing bone in a sophisticated micro-
fluidic -on-a-chip device [74]. These tools have been exploited to culture MM and 
BMSC lines, and to investigate MM chemoresistance to bortezomib, as well as the 
inducible activation of transcription factors [75]; their major limitations rely in the 
experimental procedure that does not incorporate the interplay between cancer cells 
the and surrounding stroma, critical to investigate MM progression [76].
2.3.4  3D culture of human MM tissue explants and of isolated MM cells in 
scaffolds in the microgravity-based RCCS™ bioreactor
The metabolic requirements of complex 3D cell constructs are substantially 
higher than those needed for the maintenance of traditional 2D cultures under 
static conditions. To meet this demand, dynamic bioreactors were primarily devel-
oped to optimize mass transfer, that is, gas/nutrient supply and waste elimination, 
all essential factors for preserving cell viability within large 3D cell/tissue masses. 
Among a wide array of fluid-dynamic bioreactors, the best conditions for long-term 
culture of functional 3D tissue-like bio-constructs and explants of various origin, 
including bone, were obtained with the introduction of the microgravity-based 
Rotary Cell Culture System (RCCS™, Synthecon Inc., USA) bioreactor [77–79] (a 
vast literature is available at http://www.synthecon.com). On this basis, we suc-
cessfully employed the microgravity-based RCCS™ technology for the generation 
and long-term maintenance of viable human-derived MM tissue explants and 3D 
cell constructs. Our experimental procedure for culturing human tissue samples 
was firstly validated by using normal (skin and BM) and tumor biopsies [80]. 
Then, 3D culture of human MM tissue explants was found to maintain overall 
histo-architecture integrity and viability for up to two weeks. Moreover, the system 
was suitable for assessing the impact of drugs not only on MM cells, but also on 
angiogenic vessels, as evaluated through the assessment of MVD [80]. Finally, spe-
cialized functions of both MM cells and their microenvironment, including beta-2 
microglobulin and cytokine release and metalloproteases activities, could be also 
assessed [80]. Overall, these observations suggest that 3D culture of MM tissues in 
bioreactor is feasible and can be potentially exploited as a novel translational tool 
for patient-specific drug testing.
A major limitation to a systematic pre-clinical use of this approach, however, is 
represented by the restricted availability of human MM biopsies for tissue culture, 
besides those obtained for diagnostic purposes. To overcome this limitation, we 
have recently established a novel procedure based on the reconstruction of a 3D 
surrogate MM BM microenvironment [81]. This model relies on the co-seeding 
of MM cells and stroma inside a gelatin sponge, which is subsequently cultured in 
bioreactor. Figure 1 schematically represents the procedure developed to gener-
ate MM BM surrogate microenvironments, as well as the information that can be 
obtained through the analysis of both repopulated scaffolds and culture superna-
tants. Myeloma cell lines engaged contacts with stromal cells, EC and osteoblasts, 
as assessed by histochemical and electron-microscopic analyses. Consistently, 
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pro-survival signaling and also CAM-DR, particularly through the engagement of 
the integrin VLA-4 by its counter-receptor VCAM1 [82], were significantly higher 
in 3D than in 2D parallel co-cultures. Soluble factor-mediated drug resistance could 
be also appreciated in 3D co-cultures. The system was then successfully applied 
to co-cultures of primary myeloma cells-primary myeloma BMSC and EC, allow-
ing the functionalization of myeloma-stroma interactions and MM cell long-term 
survival. Finally, the impact of bortezomib on myeloma cells and on specialized 
functions of the microenvironment could be evaluated. Significantly, the model 
also showed the potential for assessing clonal evolution ex-vivo. In fact, MM cells 
obtained from a high-risk patient actively proliferated in bioreactor, paralleling the 
elevated proliferation index observed in the patient’s bone biopsy, and anticipated 
the expansion of a clone that ultimately dominated in vivo, thus predicting the 
clinical outcome [81].
Further studies validated the use of the model for additional purposes, includ-
ing investigation on novel pathogenic interactions and preclinical drug testing. In 
particular, modeling the interaction between the receptor tyrosine kinase ROR2 and 
its ligand WNT5A in bioreactor allowed identifying this pathway as crucial in the 
Figure 1. 
Information obtainable from 3D MM- BM stroma co-culture in bioreactor. (A) Schematic representation of 
the experimental procedure: Selected elements of the BM milieu (as in b2, along with lineage-specific markers) 
and plasma cells are sequentially seeded into the scaffold and kept in culture in bioreactor. (B) Scaffolds 
retrieved from the bioreactor at the end of the culture period can be: b1: Either fixed or frozen and submitted 
to imaging by confocal, scanning electromicroscopy (SEM) or immunohistochemistry (IHC) analyses; b3: 
Lysed and processed for Western blot analysis (right) for the expression of integrins and signaling pathways 
resulting from tumor-stroma interactions, schematically represented in (left); b4: Enzymatically dissociated 
to single cells for quantification, characterization and assessment of drug-induced apoptosis by FACS analysis; 
b5: Ectopically transplanted into mice. (C) Culture medium withdrawn from the bioreactor can be processed 
to: c1: Characterize floating MM cells, reminiscent of circulating MM cells; c2: Assess specialized functions, 
attributable to both stroma and MM cells; c3: Determine the content of glycolitic metabolites; c4: Quantify 
and characterize the content of exosomes. Abbreviations: VEGF = vascular endothelial growth factor; 
IL = interleukin; Ang = angiopoietin; MMP = matrix metalloproteases; HUVEC = human umbilical vein 




adhesion of MM cells to the BM microenvironment, and as a potential therapeutic 
target for the large subgroup of MM patients whose cancer cells show ROR2 overex-
pression [83]. Moreover, the use of surrogate MM microenvironments in bioreactor 
complemented studies performed both in vitro and in animal models to exploit the 
DNA damage response as a novel therapeutic strategy for MM. In particular, the 
combination of drugs causing ATR inhibition (the compound VX-970) and mel-
phalan, a widely used alkylating agent eliciting inter-strand cross-links, proved dra-
matically effective, thus paving the way to future clinical testing [84]. An additional 
advantage provided by culture in bioreactor of MM samples or surrogate MM BM 
on scaffolds is that the well-preserved material can be frozen to create a biobank 
suitable to serially test patient-specific sensitivity, as for organoids [59].
Our surrogate BM microenvironment could also be exploited for other hemato-
logical malignancies infiltrating the BM niches. In particular, Chronic Lymphocytic 
Leukemia (CLL) is characterized by a progressive expansion of clonal CD5+ B lym-
phocytes that dynamically traffic from PB to the more protective BM and secondary 
lymphoid organs, where they acquire an aggressive phenotype and drug resistance 
[13]. In this context, new targeted therapies, namely kinase inhibitors (KI), have 
been developed to promote mobilization of leukemic cells from the hosting tissues 
into the PB, where they may re-acquire sensitivity to drug-induced apoptosis [85]. 
Our 3D surrogate BM microenvironment was exploited to recreate the niche-
specific interplay involved in CLL cells homing/mobilization, showing that distinct 
molecular interactions, in particular through the HS1 cytoskeletal protein, were 
reproduced [86]. We could demonstrate that HS1 conversion from the active to the 
inactive form, promoted by the KI ibrutinib, was able to regulate CLL cells retention 
inside- and mobilization from- scaffolds. This indicates that the model may serve 
as a good platform to unveil the mechanisms underlying tumor cells dissemination 
and to predict the impact of mobilizing agents [86], conceivably also in MM.
The same in vitro 3D dynamic culture system in RCCS™ bioreactor was used by 
Bonomi et al. [87] to generate spheroids of myeloma cells co-cultured with BMSCs. 
By that mean, the authors demonstrated that BMSCs loaded with Paclitaxel (PTX) 
could serve as a ‘Trojan horse’ to vehicle and deliver in situ anti-tumor agents in 
amounts sufficient to affect tumor growth. The inhibitory activity of PTX-primed 
BMSCs was comparable to that of PTX alone, showing that the loaded-BMSC 
strategy could be exploited to deliver drugs into the BM.
3. Conclusions and perspectives
The BM, where MM cells home, survive and accumulate, represents a complex 
and highly specialized tumor microenvironment, making the development of 
engineered 3D platforms of MM a challenging task. Indeed, in addition to a series 
of distinct ECM and cellular components, the BM microenvironment comprises 
several factors, including specialized niches, hypoxic gradients, vascularization 
and a mineralized matrix, all to be taken into account to faithfully recapitulate 
the native tumor. Nevertheless, already available pre-clinical models of MM 
represent a remarkable example of translational cancer research [88], potentially 
covering issues ranging from high- throughput drug assessment/screening to 
investigation on MM pathophysiology and patient-tailored drug testing aimed 
at precision oncology. Table 1 summarizes the main features of the previously 
described 3D models of MM BM microenvironments, together with their suitabil-
ity, in our view, to different purposes. In particular, microfluidic systems could 
be exploited for drug screening/development with high-throughput potential, in 
that they can be miniaturized to cope with the limited biological starting material 
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than can be obtained from MM patients’ samples. Most of the 3D platforms can 
be used in principle to test a selected range of drugs in a more precise microenvi-
ronmental context, in the perspective of personalized therapy and prediction of 
resistance. Finally, complex 3D technologies, such as bioreactor-based dynamic 
culture systems, while less easy to handle, can be tuned to recreate proper MM 
milieu and interactions, thus being suitable to investigation on MM pathophysiol-
ogy and the mechanisms of drugs. Future efforts combining interdisciplinary 
basic and technical proficiencies, in particular related to tissue engineering, new 
biomaterials and advanced imaging techniques [48, 89], are expected to generate 
fully-humanized, simple, cost-effective, reliable and standardized models that 
can be more widely employed in the pre-clinical setting, particularly in high-risk 
and in relapsed/resistant MM patients.






Gel scaffold Kirshner 
et al.,  
2008 [66]
ECM components 





Gel scaffold de la 
Puente  
et al.,  
2015 [67]
Fibrin gel + MM 
cells + BMSC/EC
Btz, Cfz — + +
Gel scaffold Jakubikova 










Gel scaffold Braham  










Solid scaffold Reagan  
et al., 2014
[71]
Silk scaffold+ MM 
cells +BMSC/EC
Btz — + +
Solid scaffold Fairfield 
et al.,  
2019 [72]
Silk scaffold+ MM 
cell lines+ BMSC
none — — +
Microfluidics Young  
et al.,  
2012 [75]
Microchambers 
+MM cell lines 
+BMSC




et al.,  
2018 [81]
Gelatin scaffolds 
populated by MM 
cell lines/primary 
MM cells + BMSC/









et al.,  
2017 [87]
Spheroids of 
MM cell lines + 
BMSC cultured in 
bioreactor
Paclitaxel — + —
Abbreviations: ECM = extracellular matrix; MM = Multiple Myeloma; BM = Bone Marrow; BMSC = BM stromal 
cells; EC = endothelial cells; OB = osteoblasts; Btz = bortezomib; Cfz = carfilzomib; iMIDs = immunomodulatory 
drugs; DOXO = doxorubicin; DEX = dexamethasone.
Table 1. 




In addition to the purpose of precision oncology, 3D platforms can be applied 
to explore novel pathogenic cues. In particular, several matters that are object of 
intense investigation, including hypoxia and tumor metabolism, as well as the 
contribution of exosomes and miRNAs in the interactions between tumor and its 
co-evolving microenvironment, could be fruitfully and more precisely investigated 
applying advanced technological approaches, as already done in different settings 
(Figure 1 and [90, 91]). Further exploitation of the SCID/scaffold model, based 
on the transplantation of 3D bone-like polymeric scaffolds into immunocompro-
mised mice [92], can also be envisaged to dissect biological events in primary MM 
cells engrafted inside a human BM microenvironment, as well as their response 
to drug in a in vivo context (Figure 1B). Additional future directions include the 
development and implementation of new technologies, such as microfluidic and 
bioprinting techniques, to further add to the complexity of in vitro surrogate MM 
BM microenvironments, particularly with regard to MM associated angiogenesis 
and components of the immune system.
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